Valérie Gouilleux-Gruart is Assistant Professor of Immunology at the Faculty of Medicine, Tours, France, and a biologist in the Laboratory of Immunology at the University Hospital of Tours. She is head of the FRAME research team, EA7501, GICC, Tours University, France. She completed her PhD thesis at the Pasteur Institute of Lille (1985-90) followed by three-year postdoctoral studies in Switzerland and Germany (1992-1995) before becoming Assistant Professor at University of Amiens (1995-2008) and Tours (2008-2022). She worked in three different research domains in cellular biology and immunology spanning from eosinophil biology (in Lille, France), to B cell development (in Amiens, France) and FcRn structure and functions (in Tours, France). She described for the first time the constitutive activation of the STAT5 transcription factor in acute B cell leukemia (1996). She has then specialized in the structure–function of FcRn in relationship with the development of therapeutic antibodies in the context of the laboratory of excellence (LabEx) "MAbImprove" since 2011 in Tours.
Research Keywords & Expertise
Fc Receptors
IgG
FcRn
Antibodies and microen...
Antibodies and auto-im...
Fingerprints
69%
FcRn
46%
Fc Receptors
41%
IgG
Short Biography
Valérie Gouilleux-Gruart is Assistant Professor of Immunology at the Faculty of Medicine, Tours, France, and a biologist in the Laboratory of Immunology at the University Hospital of Tours. She is head of the FRAME research team, EA7501, GICC, Tours University, France. She completed her PhD thesis at the Pasteur Institute of Lille (1985-90) followed by three-year postdoctoral studies in Switzerland and Germany (1992-1995) before becoming Assistant Professor at University of Amiens (1995-2008) and Tours (2008-2022). She worked in three different research domains in cellular biology and immunology spanning from eosinophil biology (in Lille, France), to B cell development (in Amiens, France) and FcRn structure and functions (in Tours, France). She described for the first time the constitutive activation of the STAT5 transcription factor in acute B cell leukemia (1996). She has then specialized in the structure–function of FcRn in relationship with the development of therapeutic antibodies in the context of the laboratory of excellence (LabEx) "MAbImprove" since 2011 in Tours.